Adaptin Bio Advances Novel Brain Cancer Treatment Candidate Towards Phase 1 Glioblastoma Clinical Trial

The Preston Robert Tisch Brain Tumor Center grants first IRB approval for APTN-101’s Phase I clinical trial, enabling patient recruitment to ...
ascopubs.org

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study Participants had ...
MarketWatch

Enara Bio's DARKFOX Discovery Propels ENA101, the First Ever Bispecific T Cell Engager Targeting a Cancer-Specific Dark Antigen, into IND-Enabling Studies

The MarketWatch News Department was not involved in the creation of this content. -- Enara's discovery of DARKFOX delivers on the vision of translating the dark genome into a new class of clinically ...
Nasdaq

Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases

CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, ...
BioWorld

First T-cell engager expressed locally from nanoparticle-delivered mRNA against HCC

Bispecific T-cell engagers (TCEs) aim to combat cancer by simultaneously binding T cells and tumor cells in order to induce the first to kill the second. This approach has failed to work effectively ...
Seeking Alpha

Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States

CLN-978 is the first and only development-stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases Sjögren’s disease represents the third indication under development for CLN ...
Morningstar

Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma

-- First dose-expansion cohort has been selected; dose escalation continues to identify dose for second expansion cohort -- -- Management hosting webcast and conference call today at 1:30 p.m. ET / 10 ...
MedPage Today

New Bispecific T-Cell Engager Approved for Multiple Myeloma

The FDA on Wednesday granted accelerated approval to linvoseltamab (Lynozyfic) for relapsed or refractory multiple myeloma after at least four prior lines of therapy. A B-cell maturation antigen (BCMA ...